Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. VRP.L Share Price
  4. VRP.L Share Regulatory News
  5. Verona Pharma

Pin to quick picksVRP.L Regulatory News (VRP)

VRP.L Information
  • There is currently no data for VRP

Verona Pharma

23 Oct 2020 17:30

RNS Number : 0995D
FTSE Russell
23 October 2020
 

 

 

 

 

Verona Pharma (UK): Constituent DeletionChanges in FTSE UK Index Series

23 October 2020

Subject to the expected cancellation of trading on AIM for Verona Pharma (UK, constituent), please see details of affected indexes and effective dates below:

 

 

Index

Effective FromStart of Trading

FTSE AIM All-Share Index

30 October 2020

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2020 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FTSXXLFLBBLEFBK
123456789
Date   Source Headline
30th Oct 20186:00 amGNWVerona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update
26th Oct 201810:12 amGNWData from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference
27th Sep 20187:00 amGNWVerona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018
13th Sep 20181:00 pmGNWVerona Pharma to Host Conference Call to Review Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD Presented at European Respiratory Society International Congress
7th Aug 20187:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018
2nd Mar 20184:40 pmRNSSecond Price Monitoring Extn
2nd Mar 20184:35 pmRNSPrice Monitoring Extension
30th May 20177:00 amRNSHolding(s) in Company
30th May 20177:00 amRNSHolding(s) in Company
25th May 20175:27 pmRNSHolding(s) in Company
23rd May 20178:44 amRNSHolding(s) in Company
16th May 20177:44 amRNSPartial Exercise of Over-Allotment Option
9th May 20173:36 pmRNSHolding(s) in Company
8th May 20175:33 pmRNSHolding(s) in Company
5th May 20173:32 pmRNSHolding(s) in Company
5th May 201712:15 pmRNSHolding(s) in Company
5th May 201711:36 amRNSHolding(s) in Company
3rd May 20176:02 pmRNSHolding(s) in Company
3rd May 20172:49 pmRNSBlock Listing Application and Review
3rd May 201712:34 pmRNSGrant of Options and RSUs and PDMR Dealings
2nd May 20176:10 pmRNSClosing of Global Offering and Total Voting Rights
2nd May 20177:00 amRNSDirector/PDMR Shareholding
28th Apr 20175:40 pmRNSDirector/PDMR Shareholding
27th Apr 20177:00 amRNSPricing of Offering and Approval to List on NASDAQ
19th Apr 20177:00 amRNSGlobal Offering and Application to List on NASDAQ
18th Apr 20177:00 amRNSFDA Authorisation to Proceed RPL554 Investigation
12th Apr 20171:19 pmRNSResult of AGM
4th Apr 20177:14 amRNSFiles Statement for Proposed Global Offering
4th Apr 20177:00 amRNSFiles Statement for Proposed Global Offering
4th Apr 20177:00 amRNS1st Patient Dosed in Ph2a Trial for RPL554 in CF
3rd Apr 20177:00 amRNSBoard Change
31st Mar 20177:00 amRNSCOPD Collaboration and New Commercial Director
22nd Mar 20177:00 amRNSServices Agreement with QuintilesIMS
20th Mar 20171:55 pmRNSPosting of Annual report & Notice of AGM
2nd Mar 20179:36 amRNSPDMR Dealing
27th Feb 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSNotice of Results
22nd Feb 20177:00 amRNSFirst COPD patient dosed with RPL554
13th Feb 20177:00 amRNSTotal Voting Rights & Block Listing Interim Review
8th Feb 20171:31 pmRNSResult of General Meeting and Share Consolidation
18th Jan 20177:00 amRNSPublication of Circular
11th Jan 20177:00 amRNSHolding(s) in Company
4th Jan 201710:16 amRNSHolding(s) in Company
29th Dec 20164:40 pmPRNIssue of Equity
23rd Nov 20169:17 amPRNRegistered Initial Public Offering in the US
28th Oct 20167:00 amRNSExercise of options
26th Oct 20167:00 amPRNSecond Venture and Innovation Award from the CF Trust
19th Oct 20161:00 pmPRNNotice of Cancellation of Trading on Xetra
28th Sep 201610:49 amRNSExercise of options
26th Sep 20167:00 amPRNAppointment of CFO
123456789

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
BGEU
Baillie Geu
LSE
0.98%
IPE
IPE.L
LSE
0.00%
LWI
Lowland Inv.
LSE
0.00%
VEIL
Vietnam Enterprise Investments
LSE
-1.96%
JAM
JPMorgan American
LSE
-0.66%
Trending
MPL
Mercantile Ports & Logistics
LSE
26.92%
PREM
Premier African Minerals
LSE
-7.61%
AVCT
Avacta Group
LSE
-1.40%
HEX
Helix Exploration
LSE
-0.67%
FORG
Forgent
LSE
-5.26%